Hideo Yagi
YOU?
Author Swipe
View article: Recurrent Thrombocytopenia During Caplacizumab Therapy in Acute Immune‐Mediated Thrombotic Thrombocytopenic Purpura
Recurrent Thrombocytopenia During Caplacizumab Therapy in Acute Immune‐Mediated Thrombotic Thrombocytopenic Purpura Open
View article: Prognostic relevance of early clinical and laboratory findings in immune-mediated thrombotic thrombocytopenic purpura
Prognostic relevance of early clinical and laboratory findings in immune-mediated thrombotic thrombocytopenic purpura Open
These findings suggest that early cardiac and neurologic symptoms may not be definitive predictors of iTTP-related death. Instead, extremely high lactate dehydrogenase levels indicated a worse prognosis, highlighting the need for targeted …
View article: Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum
Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum Open
Our findings suggest that AEs threaten the continued treatment of very elderly patients receiving novel agents, with careful management needed to extend the TTNT.
View article: The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients Open
Background Isatuximab, an anti-CD38 antibody, has been widely used in treatments for patients with relapsed/refractory multiple myeloma (MM). Despite its high efficacy, not all patients achieve a lasting therapeutic response with isatuxima…
View article: Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP
Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP Open
For patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP), caplacizumab, a nanobody against von Willebrand factor A1 domain, has become crucial. Delayed normalization of ADAMTS13 activity during caplacizumab therapy has …
View article: Caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura
Caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura Open
View article: Patient with Adult T-cell Leukemia and Lung Infection Caused by <i>Mycobacterium abscessus</i>: Successful Treatment with Intensive Chemotherapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation
Patient with Adult T-cell Leukemia and Lung Infection Caused by <i>Mycobacterium abscessus</i>: Successful Treatment with Intensive Chemotherapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation Open
A 63-year-old woman with adult T-cell leukemia (ATL) lymphomatous type developed a mild dry cough. Computed tomography revealed lung lesions with a tree-in-bud appearance during intensive chemotherapy. Antibodies against Mycobacterium aviu…
View article: Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023
Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023 Open
Thrombotic thrombocytopenic purpura (TTP) can rapidly become a life-threatening condition, and the importance of its appropriate diagnosis and treatment cannot be overstated. Until recently, TTP has mainly been diagnosed by clinical findin…
View article: Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin Open
View article: Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum Open
View article: Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin Open
Novel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzin…
View article: Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia
Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia Open
View article: Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis Open
Background: Little is known about the real-world survival benefits and safety profiles of carfilzomib–lenalidomide–dexamethasone (KRd) and carfilzomib–dexamethasone (Kd). Methods: We performed a retrospective analysis to evaluate their eff…
View article: Monocyte or white blood cell counts and β<sub>2</sub> microglobulin predict the durable efficacy of daratumumab with lenalidomide
Monocyte or white blood cell counts and β<sub>2</sub> microglobulin predict the durable efficacy of daratumumab with lenalidomide Open
Background: Daratumumab is one of the most widely used treatments for relapsed/refractory multiple myeloma (MM) patients. However, not all patients achieve a lasting therapeutic response with daratumumab. Objectives: We hypothesized that a…
View article: Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum
Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum Open
A total of 129 symptomatic patients with multiple myeloma (MM) who underwent high‐dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) were analyzed. The 4‐year overall survival (OS) of patients with maintenance ( n = 82)…
View article: Chronic active EBV infection in refractory enteritis with longitudinal ulcers with a cobblestone appearance: an autopsied case report
Chronic active EBV infection in refractory enteritis with longitudinal ulcers with a cobblestone appearance: an autopsied case report Open
Background Chronic active Epstein–Barr virus infection (CAEBV) is defined as Epstein–Barr virus (EBV)-positive T/NK cell-related neoplasia, and its major clinical symptom is systemic inflammation presenting as infectious mononucleocytosis,…
View article: [Treatment strategy for patients with thrombotic thrombocytopenic purpura].
[Treatment strategy for patients with thrombotic thrombocytopenic purpura]. Open
Thrombotic thrombocytopenic purpura (TTP) is a rare and potentially life-threatening disease that is characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, and ischemic organ damage resulting from the formation o…
View article: Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab
Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab Open
von Willebrand factor (VWF) is a blood glycoprotein that plays an important role in platelet thrombus formation through interaction between its A1 domain and platelet glycoprotein Ib. ARC1779, an aptamer to the VWF A1 domain, was evaluated…
View article: 〈Original〉Quality of life of chronic myelogenous leukemia patients following BCR-ABL inhibitor therapy: A multicenter study in Nara Japan using SF-8
〈Original〉Quality of life of chronic myelogenous leukemia patients following BCR-ABL inhibitor therapy: A multicenter study in Nara Japan using SF-8 Open
View article: The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017
The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017 Open
Congenital thrombotic thrombocytopenic purpura is an autosomal recessive inherited disease with a clinically heterogeneous course and an incompletely understood genotype-phenotype correlation. In 2006, the Hereditary TTP Registry started r…
View article: Bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan for relapsed follicular lymphoma: A preliminary analysis of a multicenter, prospective phase II study (BRiZ2012)
Bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan for relapsed follicular lymphoma: A preliminary analysis of a multicenter, prospective phase II study (BRiZ2012) Open
Background: Bendamustine and rituximab (BR) is a standard treatment for relapsed or newly diagnosed follicular lymphoma (FL). Despite, the role of 90Y-ibritumomab tiuxetan (90YIT) has been evaluated as consolidative therapy in FL respondin…
View article: Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry
Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry Open
We retrospectively analyzed twenty-six patients with primary plasma cell leukemia (pPCL) registered from May 2005 until April 2015 by the Kansai Myeloma Forum. Twenty patients received novel agents (bortezomib or lenalidomide), and their m…
View article: A comparison of minimal residual disease detection in autografts among ASO‐qPCR, droplet digital PCR, and next‐generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation
A comparison of minimal residual disease detection in autografts among ASO‐qPCR, droplet digital PCR, and next‐generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation Open
Relapse due to undetectable minimal residual disease (MRD) is the leading cause of death among most patients with multiple myeloma (MM) who achieved deep response. Allele-specific oligonucleotide real-time quantitative polymerase chain rea…
View article: Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome
Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome Open
Key Points Severely decreased ADAMTS13 unbound to VWF may play a key role in the pathogenesis of HELLP syndrome. A qualitative ADAMTS13 assay may be important for diagnosing HELLP syndrome.
View article: Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation
Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation Open
View article: Successful Treatment of Autoimmune Hemolytic Anemia Concurrent With Gastric Cancer by Rituximab: A Case Report of Evans Syndrome
Successful Treatment of Autoimmune Hemolytic Anemia Concurrent With Gastric Cancer by Rituximab: A Case Report of Evans Syndrome Open
The concurrence of autoimmune hemolytic anemia (AIHA), thrombocytopenic purpura (Evans syndrome) and solid cancer is rare.In this study, we report a diabetic patient with gastric cancer who developed AIHA and idiopathic thrombocytopenic pu…
View article: Rapid Restoration of Thrombus Formation and High-Molecular-Weight von Willebrand Factor Multimers in Patients with Severe Aortic Stenosis After Valve Replacement
Rapid Restoration of Thrombus Formation and High-Molecular-Weight von Willebrand Factor Multimers in Patients with Severe Aortic Stenosis After Valve Replacement Open
Bleeding tendency and loss of HMW-VWFMs observed in patients with severe AS before surgery was rapidly corrected after AVR. Instead, patients were in a VWF-predominant state between POD 8 and 22.
View article: Pathophysiology and Management of Thrombotic Thrombocytopenic Purpura
Pathophysiology and Management of Thrombotic Thrombocytopenic Purpura Open
TTPは臨床症状として微小血管性溶血性貧血，血小板減少，精神神経症状，腎機能障害，発熱の5徴候をその特徴とし，その病態はvon Willebrand因子（VWF）を特異的に切断し，その分子量サイズを減ずる作用を持つADAMTS13酵素活性著減により蓄積された超高分子量VWF重合体によるVWF依存性血小板凝集の異常亢進による全身性血栓形成である．その発症様式から先天性（家族性）であるUpshaw-Schulman症候群（USS）と後天性（非家族性）に分類され，前者ではADAM…